Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    15681523 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Conditions: Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Pemetrexed;   Drug: Bevacizumab
2 Completed Angiogenesis Inhibitors and Hypertension: Clinical Aspects
Condition: Hypertension
Intervention:
3 Completed A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel;   Drug: Trastuzumab, Docetaxel, Bevacizumab;   Drug: Trastuzumab+Docetaxel+NPLD;   Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
4 Completed Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.
Condition: Breast Cancer
Interventions: Behavioral: Exercise Training;   Behavioral: Chemo only
5 Terminated
Has Results
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Docetaxel;   Drug: CPT-11;   Drug: Paclitaxel;   Drug: Vinorelbine Tartrate;   Drug: Gemcitabine
6 Recruiting Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Conditions: Breast Cancer Recurrent;   HER2/Neu-negative Carcinoma of Breast;   Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Everolimus;   Drug: Exemestane;   Other: Patient questionaires
7 Recruiting Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
Conditions: Metastatic Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Intervention: Drug: Bevacizumab and eribulin
8 Withdrawn A Study of Bevacizumab to Prevent Malignant Ascites
Condition: Malignant Ascites
Intervention: Drug: Bevacizumab

Indicates status has not been verified in more than two years